Due: May 7, 2024 The purpose of this Funding Opportunity Announcement (FOA) is to correlate immune systemdevelopment patterns between two or more age groups- neonates, infants, and children and adolescents and further understand the impact Read More
Due: October 6, 2029 The purpose of this Notice of Funding Opportunity (NOFO) is to seek health services research grant applications focused on AHRQ research priorities, including improving healthcare quality and patient safety, improving healthcare Read More
Due: July 14, 2026 This Notice of Funding Opportunity (NOFO) encourages cooperative agreement applications for investigator-initiated, multi-site, clinical trials (Phase III and beyond) to study the effects of natural products (i.e. botanicals, probiotics, and products Read More
Due: October 21, 2024 This NOFO would support development and validation of novel clinically- and/or pathophysiologically-relevant human cellular models of ADRD. The cellular model systems would be expected to capture the multi-faceted pathologies and multiple Read More
Due: August 14, 2024 The purpose of this notice of funding opportunity (NOFO) is to solicit applications proposing innovative transdisciplinary research that integrates approaches across social/cognitive neuroscience and other social sciences and will lead to Read More
Due: July 30, 2024 Developmental Sciences supports basic research that increases our understanding of perceptual, cognitive, linguistic, social, cultural, and biological processes related to human development across the lifespan. Research supported by this program will Read More
Due: June 13, 2024 The purpose of this funding opportunity is to invite applications proposing to establish multi-scale computational models recapitulating dynamic changes associated with aging and Alzheimers disease and Alzheimers disease-related dementias (AD/ADRD). This Read More
Anticipated Release Date: Q3FY24 OR Q4FY24 Multiple Topics TBD—Possible 3 or 4 The goal of the Vaccines Capability Area is to conduct research in order to develop lead candidate vaccines and pretreatments that can be administered Read More
Due: September 18, 2024 FDA approval of a multi-drug autoinjector to reduce logistical burden on the warfighter and increase survivability Responding to this opportunity requires membership in the Medical CBRN Defense Consortium. This Consortium releases numerous Read More
Anticipated Release Date: Q1FY24 OR Q2FY24 Small Molecule Therapeutics Responding to this opportunity requires membership in the Medical CBRN Defense Consortium. This Consortium releases numerous solicitations throughout the year, so even if this opportunity may not end Read More
NTA is operated by the 501c(3) non-profit Advanced Technology International (ATI). National Technology Alliance (NTA) © 2024 - All rights reserved.